BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

MabCure, Inc. 

3702 South Virginia Street
Suite G12-401
Reno  Nevada  89502  U.S.A.
Phone: 601-432-7447 Fax:


SEARCH JOBS




Industry
Biotechnology






 Company News
MabCure, Inc. Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents 3/19/2012 8:10:17 AM
MabCure, Inc. Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand 12/16/2011 6:59:34 AM
MabCure, Inc. Receives U$500,000.00 Licensing Fee as Well as 12.5% Ongoing Royalty for Its Prostate Cancer Diagnostic Technology 11/23/2011 9:22:32 AM
MabCure, Inc. Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the Society of Gynecological Oncologists 3/8/2011 8:27:58 AM
MabCure, Inc., Corporate Update 3/1/2011 11:15:56 AM
MabCure, Inc. Secures $10 Million Funding Commitment from an Institutional Investor Managed by Roswell Capital Partners 1/20/2011 6:29:43 AM
MabCure, Inc. Welcomes Dr. Charles T. Tackney as New Chief Scientific Officer 12/6/2010 11:40:36 AM
MabCure, Inc. Completes 23.1 Million Australian Dollar Private Placement 12/6/2010 7:32:03 AM
MabCure, Inc. Generates Tumor Specific Antibodies against Prostate Cancer Which Could Lead to a Blood/Urine Diagnostic Test for Prostate Cancer 11/8/2010 12:07:54 PM
MabCure, Inc. Files Provisional Patent in the U.S. for Ovarian Cancer Antibodies 8/3/2010 9:29:27 AM
123